EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers MOST POPULAR Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 11 top tips for cutting back on alcohol January 13, 2022 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 Load more HOT NEWS Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... Pursuing precision medicine in a flagship lung cancer trial
